Haemonetics director granted 2,538 RSUs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pomeroy Claire reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Claire Pomeroy reported a grant of 2,538 restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU delivering one share of common stock upon vesting. After this award, her direct holdings total 19,410 shares of common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
Key Terms
restricted stock units financial
Amended and Restated 2019 Long-Term Incentive Compensation Plan financial
contingent right financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Haemonetics (HAE) report for director Claire Pomeroy?
When do the 2,538 RSUs granted to the Haemonetics (HAE) director vest?
What does each restricted stock unit (RSU) represent in the Haemonetics (HAE) grant?
Under which equity plan were the 2,538 RSUs granted at Haemonetics (HAE)?
AI-generated analysis. How Rhea-AI works. Not financial advice.